Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

LHRH Agonist is named as an intervention in 8 current clinical trials in our USA, UK, China, India and Ireland registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Hoffmann-La Roche (5). The most-studied condition is Breast Cancer.

Trials by status

Recruiting113%
Active, closed788%

Trials by phase

Phase 3675%
Phase 1113%
Phase 2113%

Clinical trials of LHRH Agonist

8 trials

Study	Phase	Status	Lead sponsor	Registers
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) NCT05891093 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Fudan University	China
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) NCT04546009 · Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) NCT04961996 · ClinicalTrials.gov ↗ · Early Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	Ireland, UK, USA, India, China
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) NCT05296798 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) NCT05306340 · Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Genentech, Inc.	UK, USA
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) NCT06065748 · ClinicalTrials.gov ↗ · Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA, India, China
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) NCT04576455 · ClinicalTrials.gov ↗ · Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer NCT03332797 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Active, closed	Genentech, Inc.	UK, USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with LHRH Agonist

7 conditions

Breast Cancer2Early Breast Cancer1Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer1Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer1Locally Advanced or Metastatic Breast Cancer1Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer1Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer1

By country register

Register	Trials	Recruiting
Clinical trials in USA	7	0
Clinical trials in UK	6	0
Clinical trials in China	6	1
Clinical trials in India	3	0
Clinical trials in Ireland	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about LHRH Agonist trials

How many clinical trials are testing LHRH Agonist?

8 current trials in our USA, UK, China, India and Ireland registers name LHRH Agonist as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are LHRH Agonist trials recruiting patients?

Yes. 1 of the 8 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors LHRH Agonist clinical trials?

Hoffmann-La Roche (5), Genentech, Inc (2) and Fudan University (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how LHRH Agonist works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how LHRH Agonist works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists LHRH Agonist (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

LHRH Agonist clinical trials